Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
October 24, 2025 07:00 ET Â | Source: Sagimet Biosciences Inc. Denifanstat met…
Zarminali Pediatrics Welcomes New Chief Technology Officer to Advance Patient-Centric Connected Care Model
CHICAGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Zarminali Pediatrics, the first outpatient…
London School Joins Always Active Uniform Pilot to Combat Childrens Inactivity and Obesity Levels
Wednesday 1 October, 2025 Reception pupils at Harbinger Primary School received free…
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint…
Successful Completion of First CRS with HIPEC on a 60-year-old Woman with Advanced Peritoneal Carcinomatosis
KOLKATA, India, July 28, 2025 /PRNewswire/ -- In a landmark achievement, a…
FDA Approves Apellis EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
Proven efficacy across all three key markers of disease—68% reduction in proteinuria,…
MSP Recovery Law Firm Secures Major Legal Win for MSP Recovery as Maryland Supreme Court Upholds Validity of Medicare Recovery Assignments for MSP Recovery and Its Healthcare Clients, Paving the Way for Medicare Recovery Rights Being Pursued Against GEICO
MIAMI, July 12, 2025 (GLOBE NEWSWIRE) -- MSP Recovery Law Firm, counsel…
IDEX Biometrics ASA: Mandatory notification of trades – 19 June 2025
Reference is made to the stock exchange notice from IDEX Biometrics ASA…
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese MD, proudly…